Acute myeloid leukemia (AML) is an uncommon but potentially catastrophic diagnosis with
historically high mortality rates. The standard of care treatment remained unchanged for …

FLT3 is the most frequently mutated gene in acute myeloid leukemia (AML), with FLT3
internal tandem duplication (ITD) mutations being associated with a more aggressive clinical …

Background Daunorubicin and cytarabine are used as standard induction chemotherapy for
patients with acute myeloid leukaemia. CPX-351 is a dual-drug liposomal encapsulation of …

COI notes: AE, JK, MP, GE, and MC are employed by and/or hold shares of GEMoaB GmbH.
CK is employed by CMT Cellex Manufacturing Transports and Logistics GmbH. MW and HE …

Importance Acute myeloid leukemia (AML) is a clonal hematopoietic cancer that disrupts
normal hematopoiesis, ultimately leading to bone marrow failure and death. The annual …

Nearly four decades after their conceptualization, antibody-based therapies are slowly being
added to the treatment landscape of acute myeloid leukemia (AML). While the antibody …

This is the primary report of the randomized, placebo-controlled phase 3 BRIGHT AML 1019
clinical trial of glasdegib in combination with intensive chemotherapy (cytarabine and …

Hematologic malignancies (HMs) represent a varied set of diseases ranging from indolent to
aggressive that are increasingly common in the growing older adult population …

Haematological malignancies are a heterogeneous group of diseases with diverse
incidence. In Europe, the median age at diagnosis across all disease entities is 69 years …

Outcomes in older patients with acute myeloid leukemia (AML) have historically been poor.
Given advances in low‐intensity therapy (LIT) and stem cell transplantation (SCT), we …